[PDF] high risk neuroblastoma study 1 of siop-europe

What is the SIOPEN high risk neuroblastoma study?

The SIOPEN High Risk Neuroblastoma Study (HR -NBL1) was opened in February 2002 with Ruth Ladenstein as the Principal Investigator recruiting patients from 12 countries. In parallel to HR-NBL 1 being designed, speciality committees, for example for biology and surgery, were created.

What is the International Society of Paediatric Oncology Europe neuroblastoma group?

The International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) was officially created at the Advances in Neuroblastoma Research Meeting in Bath, England in June 1998. The first clinical trial of SIOPEN was Infant Neuroblastoma European Study (INES), which four trials and opened in 1999.

What is the first clinical trial of SIOPEN?

The first clinical trial of SIOPEN was Infant Neuroblastoma European Study (INES), which four trials and opened in 1999. The Study was led by Mary Gerrard, Bruno de Bernard, Jean Michon, Herve Rubie and Adela Canete and recruited patients from nine countries.

Can standard risk stratification and treatment improve outcomes for children with neuroblastoma?

Standard risk stratification and treatment explicitly adapted to graduated resource settings can improve outcomes for children with neuroblastoma by reducing preventable toxic death and relapse. Keywords: MYCN; Neuroblastoma; diagnosis; low income countries; resource limited countries; treatment. © 2015 The Authors.